Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: THC stock price vs DHR: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at DHR's multiple
Needs DHR P/E.
Implied fair value · at THC's multiple
Needs THC P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
TENET HEALTHCARE CORP · implied price per share
Bear
$105.38
Base
$143.97
Bull
$194.22
DANAHER CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
HCA Healthcare, Inc.
THC vs HCA
UNIVERSAL HEALTH SERVICES INC
THC vs UHS
COMMUNITY HEALTH SYSTEMS INC
THC vs CYH
Encompass Health Corp
THC vs EHC
SELECT MEDICAL HOLDINGS CORP
THC vs SEM
Acadia Healthcare Company, Inc.
THC vs ACHC
AGILENT TECHNOLOGIES, INC.
THC vs A
ILLUMINA, INC.
THC vs ILMN
JOHNSON & JOHNSON
THC vs JNJ
ABBOTT LABORATORIES
THC vs ABT
LOEWS CORP
THC vs L
BERKSHIRE HATHAWAY INC
THC vs BRK-B
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe THC can sustain its current growth and ROIC while reducing leverage without meaningful margin compression, then THC looks attractive relative to DHR on valuation; however, if you require a like-for-like quality premium to justify paying up, the DHR comparison argues for caution because THC’s lower margins and higher leverage do not support a full DHR multiple rerating.
THC trades at a sharp discount to DHR on headline multiples, with P/E at 16.9x versus 40.5x, P/S at 1.0x versus 5.9x, and EV/EBITDA at 5.7x versus 19.5x. The model implies a much higher price for THC, but DHR-based result likely overstates value because DHR is a higher-quality diversified life sciences company with structurally different margin and capital profiles.
Supporting Metrics
